Yeast Protein for Muscle Mass
7. september 2026 oppdatert av: University of Alberta
Yeast Protein for Muscle Anabolism: A Randomized Controlled Trial
Protein supplementation is said to be one of the cost-efficient and practical strategies to meet protein needs for growth and exercise, and can help maximize muscle gain from resistance exercise.
It facilitates faster recovery from stress-induced tissue damage and enhances performance output.
Protein sources derived from animal products are generally recognized as the highest quality protein.
However, altering the protein composition of a protein source can improve the protein quality.
The yeast protein supplement the investigators will use in this study has a similar amino acid composition to whey protein, which is derived from an animal product, but it is produced more sustainably.
The study aims to compare the effects of yeast and whey protein on muscle mass over 16 weeks.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a double-blinded randomized clinical trial of a 16-week nutrition intervention with yeast and whey protein in 72 people (36 per group; 18 male and 18 female) between the ages of 18 and 35, recruited from the University of Alberta campus, Edmonton, Canada. Consenting participants will be randomly assigned to one of two groups: whey protein or yeast protein by the study coordinator, who will not collect study outcome measurements or analyze the data.
The goal of the trial is to determine if consumption of 40 g per day of yeast protein produces similar effects to 40 g supplementation with whey protein. It is anticipated that daily yeast protein consumption will show similar gains in muscle mass and improvement in immune function, increased diversity in gut microbiota, and amino acid-derived metabolites compared to whey protein.
Studietype
Intervensjonell
Registrering (Antatt)
72
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Jianping Wu, PhD
- Telefonnummer: (780) 492-6885
- E-post: jwu3@ualberta.ca
Studiesteder
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2R3
- The University of Alberta North Campus
-
Ta kontakt med:
- Jianping Wu, PhD
- Telefonnummer: (780) 492-6885
- E-post: jwu3@ualberta.ca
-
Hovedetterforsker:
- Jianping Wu, PhD
-
Hovedetterforsker:
- Vera Mazurak, PhD
-
Hovedetterforsker:
- Normand Bouleé, PhD
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Participants must have the ability to read, understand, and sign an informed consent and must be willing to comply with study treatment and follow-up.
- Prior resistance training experience (defined as performing resistance exercises >1/week for the past 3 months or longer) to enable them to reach a large training stimulus relatively quickly and to avoid the longer phase of neuromuscular adaptations
- ≥18 years and <35 years of age
Exclusion Criteria:
- Diabetes, musculoskeletal disease, cancer, Crohn's disease, or any other acute or chronic condition that interferes (or the medication prescribed for those conditions) with muscle anabolism.
- Diagnosed with or being treated for heart disease, stroke, high blood pressure 130/80 mmHg or higher
- Pain/discomfort/pressure in the chest during activities of daily living or physical activity
- Pregnant or not on adequate contraception.
- A known hypersensitivity/allergy to ingredients in the supplements.
- Inflammatory bowel diseases
- Enrolment in any other clinical protocol or investigational study that may interfere with study procedures
- Taking antibiotics
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Whey protein
|
Lower and upper body resistance training exercises 3 times a week for 16 weeks
60g of protein supplement (40g of protein).
Oral administration, 30g during exercise and anytime after exercise, or 30g in the morning and evening if no exercise is performed for a period of 16 weeks.
|
|
Eksperimentell: Yeast Protein
|
Lower and upper body resistance training exercises 3 times a week for 16 weeks
60g of protein supplement (40g of protein).
Oral administration, 30g during exercise and anytime after exercise, or 30g in the morning and evening if no exercise is performed for a period of 16 weeks.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in muscle mass
Tidsramme: 16 weeks
|
The primary outcome of the study is the change in muscle mass.
It is hypothesized that participants consuming yeast protein will show an increase in appendicular lean mass similar to that observed with whey protein.
|
16 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in muscle function, inflammatory biomarkers, oxidative stress markers, gut microbiota and metabolites
Tidsramme: 16 weeks
|
The secondary outcomes of the study include changes in muscle function, which will be assessed through one repetition maximum (1RM) testing for both the bench press and leg press.
Additionally, the investigators will evaluate inflammatory biomarkers, specifically plasma cytokines, as well as oxidative stress markers such as glutathione, total antioxidant capacity, and protein carbonyl levels.
The study will also investigate gut microbiota and metabolites.
The investigators hypothesize that the secondary outcomes will show similar effects in participants taking yeast protein compared to those taking whey protein.
|
16 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Cermak NM, Res PT, de Groot LC, Saris WH, van Loon LJ. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. Am J Clin Nutr. 2012 Dec;96(6):1454-64. doi: 10.3945/ajcn.112.037556. Epub 2012 Nov 7.
- Patel S. Emerging trends in nutraceutical applications of whey protein and its derivatives. J Food Sci Technol. 2015 Nov;52(11):6847-58. doi: 10.1007/s13197-015-1894-0. Epub 2015 Jun 9.
- West DWD, Abou Sawan S, Mazzulla M, Williamson E, Moore DR. Whey Protein Supplementation Enhances Whole Body Protein Metabolism and Performance Recovery after Resistance Exercise: A Double-Blind Crossover Study. Nutrients. 2017 Jul 11;9(7):735. doi: 10.3390/nu9070735.
- Norton LE, Wilson GJ, Layman DK, Moulton CJ, Garlick PJ. Leucine content of dietary proteins is a determinant of postprandial skeletal muscle protein synthesis in adult rats. Nutr Metab (Lond). 2012 Jul 20;9(1):67. doi: 10.1186/1743-7075-9-67.
- Joy JM, Lowery RP, Wilson JM, Purpura M, De Souza EO, Wilson SM, Kalman DS, Dudeck JE, Jager R. The effects of 8 weeks of whey or rice protein supplementation on body composition and exercise performance. Nutr J. 2013 Jun 20;12:86. doi: 10.1186/1475-2891-12-86.
- Banaszek A, Townsend JR, Bender D, Vantrease WC, Marshall AC, Johnson KD. The Effects of Whey vs. Pea Protein on Physical Adaptations Following 8-Weeks of High-Intensity Functional Training (HIFT): A Pilot Study. Sports (Basel). 2019 Jan 4;7(1):12. doi: 10.3390/sports7010012.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. september 2026
Primær fullføring (Antatt)
1. juli 2027
Studiet fullført (Antatt)
1. juli 2029
Datoer for studieregistrering
Først innsendt
24. april 2026
Først innsendt som oppfylte QC-kriteriene
24. april 2026
Først lagt ut (Faktiske)
1. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
9. september 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
7. september 2026
Sist bekreftet
1. september 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Pro00156043
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-planbeskrivelse
Only researchers who have the training and experience to do the research (also known as "qualified researchers") will be allowed to use the data.
IPD collected throughout the trail will be shared on request and with ethics approval after the study results have been accepted and published
IPD-delingstidsramme
IPD will be available for 15 yrs
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .